Drug Profile
Research programme: SSAO/VAP-1 protein inhibitors - Syntara Limited
Alternative Names: PXS4159; PXS4206Latest Information Update: 13 Dec 2023
Price :
$50
*
At a glance
- Originator Pharmaxis
- Developer Syntara Limited
- Class Small molecules
- Mechanism of Action AOC3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma